5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

When I last wrote about the pharmaceuticals company Bristol-Myers Squibb Company (NYSE: BMY ) in August, I had given it a Sell rating for the short term. This was based on the likelihood of a price drop on the releaseManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Gia ...